Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION For the quarterly period ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40970 Deep Medicine Acquisition Corp. (Exact name of registrant as specified in its charter) | Delaware | 85-3269086 | | --- | --- ...

Financial Performance - For the three and six months ended September 30, 2022, the company reported a net loss of $165,559 and $319,979, respectively, with operating costs of $717,723 and $987,556, offset by interest earned on marketable securities of $552,164 and $667,577[105]. - The company incurred cash used in operating activities of $362,426 for the six months ended September 30, 2022, compared to $173,596 for the same period in 2021[107]. - The company has not generated any revenues to date and expects to generate non-operating income in the form of interest income on cash and cash equivalents after the IPO[104]. Cash and Liabilities - As of September 30, 2022, the company had cash of $514,673 and total current liabilities of $1,026,513, resulting in a working capital deficit of $331,863, a decrease of $987,556 compared to March 31, 2022[106]. - Cash and marketable securities held in the Trust Account increased by $667,577 to $128,428,444 as of September 30, 2022, compared to $127,760,867 as of March 31, 2022[106]. - The company has available cash of $514,673 held outside the trust account for identifying and evaluating target businesses[111]. Business Combination Plans - The company expects to incur approximately $400,000 for legal, accounting, due diligence, and other expenses associated with business combinations, along with $50,000 for regulatory reporting fees and $75,000 for Nasdaq continued listing fees[114]. - The company intends to use substantially all funds held in the trust account to complete its initial business combination, with an estimated annual franchise tax obligation of $200,000[109]. - The company expects to continue incurring significant costs in pursuit of its initial business combination plans[102]. - The company terminated the Business Combination Agreement with Chijet on September 26, 2022, without incurring any penalties[97]. - The company may need additional financing to complete the initial business combination if target businesses exceed the net proceeds from the IPO[116]. Financing and Loans - A loan of $500,000 from the sponsor was utilized for IPO expenses, with the loan being non-interest bearing and due upon the completion of the initial business combination[120]. - The company issued two promissory notes totaling $1,265,000 to sponsor affiliates to extend the Combination Period from October 29, 2022, to January 29, 2023[123]. - The company may convert up to $1,500,000 of working capital loans into private placement-equivalent units at a price of $10.00 per unit[121]. Regulatory and Compliance - The company is required to register certain securities for sale under the Securities Act as per the registration rights agreement with initial stockholders[122]. - There are no caps on the reimbursement of out-of-pocket expenses incurred by the sponsor or affiliates for identifying potential target businesses[119]. Market Conditions - Economic uncertainties, including inflation and geopolitical instability, may adversely affect the company's results and ability to complete a Business Combination[126]. - The company does not anticipate needing to raise additional funds post-IPO for due diligence and operational expenses related to the proposed Business Combination[116]. Share Issuance - The company plans to issue 300,000 shares to officers and directors post-business combination, subject to lock-up restrictions[118]. Off-Balance Sheet Arrangements - As of September 30, 2022, the company reported no off-balance sheet arrangements or contractual obligations, indicating no operational activities to date[124].

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40970 Deep Medicine Acquisition Corp. (Exact name of registrant as specified in its charter) | --- | --- | --- | |--------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended March 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File No. 001-40970 DEEP MEDICINE ACQUISITION CORP. | --- | --- | |----------------------------------------------------------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40970 Deep Medicine Acquisition Corp. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-40970 | --- | --- | |------------------------------------------------------------------------------------------------------------- ...